<i>IL21R</i> hypomethylation as a biomarker for distinguishing benign and malignant breast tumours-Reference-Cited by-同舟云学术

IL21R hypomethylation as a biomarker for distinguishing benign and malignant breast tumours

Published:2024-05-09 Issue:1 Volume:19 Page:
ISSN:1559-2294
Container-title:Epigenetics
language:en
Short-container-title:Epigenetics

Author:

Zang Zishan¹,Yin Yifei²,Liu Chunlan¹,Zhu Qiang¹,Huang Xuandong²,Li Hong³,Yang Rongxi¹^ORCID

Affiliation:

1. Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China

2. Department of Thyroid and Breast Surgery, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, Huaian, China

3. Department of Pathology, The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an, Huaian, China

Funder

the Research Grant of Nanjing Medical University and Jiangsu Province

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/15592294.2024.2352683

Reference61 articles.

1. Breast Cancer Epidemiology, Prevention, and Screening

2. Awareness and current knowledge of breast cancer

3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

4. Core needle biopsy of benign, borderline and in-situ problematic lesions of the breast: Diagnosis, differential diagnosis and immunohistochemistry

5. Clinical Diagnosis and Management of Breast Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Therapeutic Implications of Cell Division Cycle 20 Homolog in Breast Cancer;Cancers;2024-07-15